<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638517</url>
  </required_header>
  <id_info>
    <org_study_id>TELO-SCOPE</org_study_id>
    <nct_id>NCT04638517</nct_id>
  </id_info>
  <brief_title>The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis</brief_title>
  <official_title>The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TELO-SCOPE is a national, multi-centre, double-blind, placebo-controlled, randomised (2:1)&#xD;
      trial which will test the hypothesis that, compared to placebo, the addition of danazol to&#xD;
      standard of care in pulmonary fibrosis associated with short telomeres is safe and will&#xD;
      result in reduced telomere attrition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TELO-SCOPE is a national, multi-centre, double-blind, placebo-controlled, randomised trial&#xD;
      which will be conducted in subjects aged &gt;5 years with a multi-disciplinary diagnosis of&#xD;
      pulmonary fibrosis and with age-adjusted telomere length below the 10th centile in adults;&#xD;
      and for children (age &lt; 16 years), a confirmed diagnosis of Dyskeratosis Congenita (DC).&#xD;
      Consenting participants who meet all other inclusions and no exclusions will be randomised&#xD;
      (n=50, 2:1 (danazol:placebo)) to receive danazol (maximum tolerated dose (up to 800mg daily,&#xD;
      two-divided doses) or matched placebo, for 12 months in addition to standard of care&#xD;
      background therapy. The primary outcome is change in telomere length at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in absolute telomere length from baseline (base pairs)</measure>
    <time_frame>12 months</time_frame>
    <description>Telomere length will be measured in absolute terms (base pairs) using the telomere shortest length assay (TeSLA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death or Non-Elective Hospitalisation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in telomere length from baseline to 3, 6 and 9 months (base pairs)</measure>
    <time_frame>3, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced vital capacity (FVC) at 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>FVC is measured as the volume of air exhaled during spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diffusing capacity for carbon monoxide at 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>DLCO is a measurement of the of the lung's gas transfer ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk distance from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leicester cough questionnaire (LCQ) from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parent cough-specific quality of life (PCSQoL) from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Telomere Shortening</condition>
  <condition>Telomere Disease</condition>
  <condition>Dyskeratosis Congenita</condition>
  <arm_group>
    <arm_group_label>Danazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danazol</intervention_name>
    <description>Danazol up to 800mg daily in two-divided doses.</description>
    <arm_group_label>Danazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females aged &gt;5 years, able to take capsules orally.&#xD;
&#xD;
          2. Fibrosing interstitial pneumonia (Idiopathic PF, idiopathic non-specific interstitial&#xD;
             pneumonia, chronic hypersensitivity pneumonitis, pleuroparenchymal fibroelastosis,&#xD;
             unclassifiable interstitial lung disease (ILD)) diagnosed according to the current&#xD;
             international guidelines.&#xD;
&#xD;
          3. Age-adjusted peripheral blood leukocyte telomere length &lt; 10th centile on Flow-FISH.&#xD;
&#xD;
          4. FVC &gt; 40% predicted.&#xD;
&#xD;
          5. DLCO &gt; 25% predicted.&#xD;
&#xD;
          6. If receiving background pirfenidone / nintedanib, stable dose for 28 days prior to&#xD;
             screening.&#xD;
&#xD;
          7. Able to understand and sign a written informed consent form (or legally authorised&#xD;
             representative).&#xD;
&#xD;
          8. Agreement to use a medically approved form of non-hormonal contraception (if of&#xD;
             child-bearing potential) (noting that oral contraceptives are advised not to be used&#xD;
             concurrently with danazol).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Actively or imminently listed for lung transplantation.&#xD;
&#xD;
          2. Undergone, awaiting, or likely to require bone marrow transplantation within 12&#xD;
             months.&#xD;
&#xD;
          3. Concurrent enrolment in another study.&#xD;
&#xD;
          4. Females with a positive pregnancy test at screening or currently breastfeeding.&#xD;
&#xD;
          5. Pelvic infection.&#xD;
&#xD;
          6. Past jaundice with oral contraceptives.&#xD;
&#xD;
          7. Undiagnosed abnormal genital bleeding.&#xD;
&#xD;
          8. Undiagnosed ovarian/uterine masses&#xD;
&#xD;
          9. Any history of malignancy likely to result in significant disability or likely to&#xD;
             require significant medical or surgical intervention within the next 12 months.&#xD;
&#xD;
         10. History of androgen-dependent tumour.&#xD;
&#xD;
         11. Any condition other than PF that, in the opinion of the investigator, is likely to&#xD;
             result in the death of the participant within the next 12 months.&#xD;
&#xD;
         12. History of end-stage liver disease or ALT or AST &gt; 3 times the upper limit of normal.&#xD;
&#xD;
         13. History of end-stage kidney disease requiring dialysis.&#xD;
&#xD;
         14. Markedly impaired cardiac function.&#xD;
&#xD;
         15. Known increased risk of or history of thromboembolism (e.g. Factor V Leiden, Protein C&#xD;
             or S deficiency).&#xD;
&#xD;
         16. Uncontrolled hypertension.&#xD;
&#xD;
         17. Uncontrolled lipoprotein disorder.&#xD;
&#xD;
         18. Poorly-controlled diabetes mellitus.&#xD;
&#xD;
         19. History of marked or persistent androgenic reaction to previous gonadal steroid&#xD;
             therapy.&#xD;
&#xD;
         20. History of epilepsy induced or worsened by previous gonadal steroid therapy.&#xD;
&#xD;
         21. History of raised intracranial pressure.&#xD;
&#xD;
         22. Known intolerance to danazol.&#xD;
&#xD;
         23. Porphyria.&#xD;
&#xD;
         24. Use of any of the following agents within 28 days before screening: danazol or other&#xD;
             androgen therapy, warfarin or other anticoagulant, carbamazepine, phenytoin,&#xD;
             investigational therapy, cytotoxic therapy, tacrolimus, cyclosporine, simvastatin.&#xD;
&#xD;
         25. Professional singer due to potential for voice change.&#xD;
&#xD;
         26. Competitive athletes.&#xD;
&#xD;
         27. Lactose intolerance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Chambers</last_name>
    <phone>07 3139 4000</phone>
    <email>daniel.chambers@health.qld.gov.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Grainge</last_name>
      <phone>02 4042 1603</phone>
      <email>Christopher.grainge@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Jaffe</last_name>
      <phone>02 9382 5500</phone>
      <email>a.jaffe@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamera Corte</last_name>
      <phone>02 9515 6120</phone>
      <email>tameracorte@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Westmead</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiran Selvadurai</last_name>
      <phone>02 9845 3395</phone>
      <email>hiran.selvadurai@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Mackintosh</last_name>
      <phone>07 3139 5695</phone>
      <email>john.mackintosh@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Reynolds</last_name>
      <phone>08 7074 2763</phone>
      <email>paul.reynolds@adelaide.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Glaspole</last_name>
      <phone>03 9076 2000</phone>
      <email>iglaspole@lasv.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Austin</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Goh</last_name>
      <email>nicole.goh@austin.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Wrobel</last_name>
      <phone>08 6152 4029</phone>
      <email>jeremy.wrobel@health.wa.gov.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be analysed and shared with collaborators with the plan to publish the results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

